Assessment cycle 2024 Q2

Record of documents ratified in the 2024 Q2 assessment cycle.

Consultation on the second version of the framework the Institute uses to rate certainty in a body of evidence. The revision retains the four-level GRADE scale and…

Consultation on the policy governing the public register of Institute members, reviewers, correspondents and contributors: who appears, what is published about each, and…

Consultation on the draft monograph for IGF-1 LR3, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft monograph for Kisspeptin-10, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft monograph for LL-37, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…

Consultation on the draft monograph for Petrelintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft of CEI-MS-03, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…

Consultation on the draft of CEI-MS-15, which specifies the performance a determination must achieve for documentation and states what the resulting figure does not…

Consultation on the draft of this intervention review, which registers the question: Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist…

What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a…

What can be concluded from a development programme that was discontinued, and how should the Institute record it?

What is the relationship between the indications in which melanocortin receptor agonists have been evaluated and the uses under which they are supplied?

A disorder of glucose regulation characterised by insulin resistance with relative insulin deficiency, diagnosed by glycated haemoglobin, fasting plasma glucose or oral…

Slowed gastric transit, considered here both as a pharmacodynamic mechanism and as an adverse-effect surface relevant to procedural and anaesthetic risk.

Fixed-ratio combination of a long-acting amylin analogue and a GLP-1 receptor agonist. The combination pairs two complementary satiation mechanisms: GLP-1 receptor agonism acting on hypothalamic and hindbrain appetite…

Synthetic tetrapeptide. Epithalon is supplied on the premise that it activates telomerase and thereby extends replicative lifespan, on the basis of cell-culture reports of…

Mitochondrial-derived 16-residue peptide. MOTS-c is described as a mitochondrial-encoded regulator of metabolic homeostasis that acts through the folate one-carbon cycle to raise…

Mitochondria-targeted cardiolipin-binding tetrapeptide. Elamipretide binds cardiolipin in the inner mitochondrial membrane, stabilising cristae curvature and the assembly of electron-transport-chain…

Determination of water content in lyophilised peptides by coulometric Karl Fischer titration

Identification and quantification of counter-ions in synthetic peptide salts

Peptides, SARMs, injectable oils and raw materials.

Peptides, oligonucleotides, SARMs, injectable oils and raw materials. 350+ catalogue lines.

Peptides, SARMs and raw materials. 350+ catalogue lines.

Peptides, SARMs, injectable oils and raw materials.